BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.
- None.
- None.
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021.
Dr. Bill Williams, BriaCell's President and CEO, will deliver his corporate presentation at 1:15pm ET on September 29. Management will be available for one-on-one meetings to be held throughout the conference. Investors can register to receive a free spectator pass for the event: https://www.benzinga.com/events/small-cap/healthcare/.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management’s Discussion and Analysis, under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
What is the date of BriaCell's presentation at the Benzinga Healthcare Small Cap Conference?
Who will be presenting for BriaCell at the Benzinga Healthcare Small Cap Conference?
What is the focus of BriaCell Therapeutics Corp.?
How can investors register for the Benzinga Healthcare Small Cap Conference?
What time is BriaCell's presentation during the conference?
